Factors to consider before selecting the therapeutic target in a patient with SLE
| Timing | Type I IFN activation is most prominent early in the disease process and during some flares |
| IFN inducer | Several IFN inducers exist and may differ between patients. Prevent generation of IFN inducers or degrade triggers? Block sensors of IFN inducers? |
| IFN-producing cells | Inhibit pDCs and/or other cell types as well? |
| Type of IFN | Which IFN(s) are most relevant in a specific patient? |
| IFN target | Block IFN receptor(s) or signalling pathways? |
IFN, interferon; pDC, plasmacytoid dendritic cell.